Homegrown drug major Sun Pharma on Wednesday entered into a partnership with AstraZeneca for distribution of the latter’s diabetes medicine dapagliflozin in India.
As part of the pact, Sun Pharma will sell AstraZeneca’s dapagliflozin, a Type 2 diabetes medicine, under brand name Oxra. AstraZeneca India markets dapagliflozin under the brand name Forxiga. Both the companies would promote, market and distribute dapagliflozin in India under their respective brand names, Sun Pharma said in a statement. AstraZeneca will retain the intellectual property rights to dapagliflozin, it added. Sun Pharma CEO – India Business Abhay Gandhi said: “The addition of this innovative Type 2 diabetes treatment bolsters our diabetes portfolio. We believe that the extended portfolio will further enhance our service capabilities to offer customers and patients innovative medicines at affordable prices.”